EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity

Christopher D Putnam iD, Lori Broderick iD, Hal M Hoffman iD

Immunological Reviews · 2024-03 · 322 (1) · 259-282

DOI: 10.1111/imr.13292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 25.12.2023. Verfasst von Christopher D Putnam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Cryopyrin-Associated Periodic Syndromes. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From studies of individual families to global collaborative efforts, the NLRP3 inflammasome is now recognized to be a key regulator of innate immunity. Activated by a panoply of pathogen‐associated and endogenous triggers, NLRP3 serves as an intracellular sensor that drives carefully coordinated assembly of the inflammasome, and downstream inflammation mediated by IL‐1 and IL‐18. Initially discovered as the cause of the autoinflammatory spectrum of cryopyrin‐associated periodic syndrome (CAPS), NLRP3 is now also known to play a role in more common diseases including cardiovascular disease, gout, and liver disease. We have seen cohesion in results from clinical studies in CAPS patients, ex vivo studies of human cells and murine cells, and in vivo murine models leading to our understanding of the downstream pathways, cytokine secretion, and cell death pathways that has solidified the role of autoinflammation in the pathogenesis of human disease. Recent advances in our understanding of the structure of the inflammasome have provided ways for us to visualize normal and mutant protein function and pharmacologic inhibition. The subsequent development of targeted therapies successfully used in the treatment of patients with CAPS completes the bench to bedside translational loop which has defined the study of this unique protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinCryopyrin-Associated Periodic SyndromesHumansMiceAnimalsInflammasomesImmunity, InnateInflammationInterleukin-1beta

Stichwörter der Autor:innen

NLRP3cryopyrin-associated periodic syndromefamilial cold autoinflammatory syndromeinflammasome

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesInterleukin-1beta

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.
  • Rady Children's Hospital, San Diego, California, USA.

ORCID-Profile: Christopher D Putnam, Lori Broderick, Hal M Hoffman

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Putnam, C. D., Broderick, L., & Hoffman, H. M. (2024). The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity. Immunological Reviews, 322(1), 259-282. https://doi.org/10.1111/imr.13292

Vancouver

Putnam CD, Broderick L, Hoffman HM. The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity. Immunological Reviews. 2024;322(1):259-282. doi:10.1111/imr.13292

BibTeX
@article{Putnam2024,
  author = {Putnam, Christopher D and Broderick, Lori and Hoffman, Hal M},
  title = {The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity},
  journal = {Immunological Reviews},
  year = {2024},
  volume = {322},
  number = {1},
  pages = {259--282},
  doi = {10.1111/imr.13292}
}
Kostenlos starten →